Quanterix Stock Price, News & Analysis

Quanterix Corporation (NASDAQ: QTRX), a biomarker detection company, has scheduled its first quarter 2025 financial results announcement for May 12, 2025. The company will release its Q1 2025 results after market close, followed by a conference call at 4:30 p.m. E.T.

Investors can participate in the conference call by dialing (800) 715-9871 or (646) 307-1963 with conference ID 7353673. A live webcast will be available on the News & Events page of Quanterix's website, with the replay accessible for one year.

Kent Lake, holding 7.7% of Quanterix shares, has strongly criticized the company's amended merger agreement with Akoya Biosciences. The key issue is Quanterix's decision to remove shareholders' voting rights on the merger, despite reports showing nearly 3-to-1 opposition to the deal.

The statement highlights concerning financial impacts, noting that Quanterix's stock price has fallen 48% and enterprise value has declined over 100% since the merger announcement. Kent Lake directly challenges CEO Masoud Toloue's claim about the merger's "strong strategic merits."

In response, Kent Lake will continue its push to elect three new board members at the upcoming Annual Meeting, arguing that the current board has proven unable to represent shareholder interests effectively. The investor views this boardroom change as increasingly urgent following what they describe as a "value-destructive transaction" and "shocking disenfranchisement" of shareholders.

Quanterix and Akoya Biosciences have announced amended merger terms, revising their previous agreement. Under the new terms, Quanterix will issue approximately 7.76 million shares and pay $20 million in cash to Akoya shareholders. Each Akoya share will receive $0.38 in cash and 0.1461 Quanterix shares.

The revised deal structure results in 9 million fewer shares being issued compared to the original terms. Post-merger ownership will be split with Quanterix shareholders holding approximately 84% and Akoya shareholders owning 16% of the combined company.

The amended agreement has received approval from both companies' boards, with over 50% of Akoya shareholders agreeing to vote in favor. The merger is expected to close in Q2 2025, subject to standard closing conditions. Goldman Sachs is advising Quanterix, while Perella Weinberg Partners is serving as Akoya's financial advisor.

Kent Lake, holding 7.7% of Quanterix (NASDAQ: QTRX) shares, has filed a definitive proxy statement opposing the proposed merger with Akoya Biosciences (NASDAQ: AKYA). The investment firm has issued a letter to shareholders urging them to vote AGAINST both merger-related proposals at the upcoming special meeting scheduled for May 13, 2025.

Kent Lake characterizes the merger as 'value-destructive' and 'deeply unfair,' describing it as effectively a bailout for Akoya at Quanterix shareholders' expense. The firm has raised concerns about the transaction process and potential conflicts of interest among Quanterix board members. Shareholders can access additional voting information and resources at www.SaveQTRX.com.

Tikvah Management , owning approximately 1.5% of Quanterix Corp. (QTRX), has expressed serious concerns regarding Quanterix's recent agreement to purchase up to $30 million in convertible notes from Akoya Biosciences (AKYA).

The investment firm highlighted three major concerns: 1) Akoya's need for bridge financing indicates potential financial distress, 2) the timing of the capital commitment before the shareholder vote on the proposed Quanterix-Akoya merger is questionable, and 3) the convertible notes' terms are considered unfavorable to Quanterix shareholders.

Tikvah has reaffirmed its intention to vote AGAINST the proposed merger between Quanterix and Akoya at the upcoming Special Meeting, while reserving the right to change its position based on new developments.

Kent Lake, holding approximately 7.5% of Quanterix (NASDAQ: QTRX) shares, has expressed strong opposition to Quanterix's recent $30 million convertible notes agreement with Akoya Biosciences (NASDAQ: AKYA).

The agreement, part of a broader merger deal, allows Akoya to sell convertible notes to Quanterix until July 2025, even if the merger is terminated. Kent Lake criticizes this as a 'backdoor financing' arrangement, highlighting that Akoya faces a 'near-term liquidity crisis' and arguing that Quanterix shareholders will be left with 'high-risk subordinated distressed debt'.

Kent Lake claims the Board violated fiduciary duties by not providing comprehensive disclosures on the bridge financing terms and lacking a fairness opinion. They urge shareholders to vote AGAINST both merger-related proposals.

Quanterix (NASDAQ: QTRX) has unveiled a new dried blood spot (DBS) extraction kit for their Simoa® assay platform at the AD/PD conference in Vienna. The innovative kit aims to revolutionize neurodegenerative disease testing by enabling biomarker measurement from dried blood spots, offering a more cost-effective and less invasive alternative to traditional venous blood draws.

The DBS extraction kit, developed in collaboration with the DROP-AD Project at the University of Gothenburg, includes buffers and sample preparation protocols. Validation studies demonstrated correlation rates of 0.75 to 0.86 between DBS samples and venous samples in simulated CSF testing using Simoa ALZpath p-Tau 217.

The company's Simoa® technology is being featured in over 80 posters and presentations at the conference, highlighting its impact on neurodegenerative disease research. This advancement aims to improve accessibility to biomarker testing, particularly in remote or resource- settings, and expand participation in Alzheimer's research among under-represented populations.

Tikvah Management , holding approximately 1.5% of Quanterix Corp. (QTRX) shares, has announced its intention to vote against the proposed merger with Akoya Biosciences (AKYA) at the upcoming Quanterix Special Meeting. As a significant investor since 2018, Tikvah opposes the merger citing three main concerns:

• Undervaluation of Quanterix shares in the proposed deal
• Expected significant reduction in company cash flow post-merger
• Quanterix's business superiority compared to Akoya's

Tikvah has noted that other investors have also publicly expressed opposition to the merger, though they maintain the right to change their position if significant new developments arise.

Sera Prognostics (Nasdaq: SERA) announced significant changes to its Board of Directors. Jeff Elliott, currently a senior advisor at Boston Consulting Group and board member of Quanterix , will join the board on March 20, 2025. Elliott brings extensive experience in corporate strategy, business operations, and commercializing molecular diagnostics, having previously served as CFO and COO at Exact Sciences.

The company also announced that Ryan Trimble will retire and step down as director on June 30, 2025, after 14 years of service. Additionally, Marcus Wilson will not seek re-election at the 2025 Annual Meeting of Stockholders. Both departures are part of the board's ongoing efforts to refresh its composition and expertise.

These changes come at a important time as Sera begins leveraging its recent PRIME study results to build market presence for its PreTRM® test, focusing on improving maternal and neonatal health through pregnancy biomarker information.